Evonetix appoints new CEO to support DNA platform  

Synthetic biology company Evonetix has appointed a new Chief Executive Officer (CEO) to support the company’s next phase of product development.  

The company has appointed Colin McCracken as CEO with immediate effect. McCracken has over 20 years of experience and will support Evonetix in the development and commercialisation of its semiconductor-based DNA synthesis platform. 

Prior to Evonetix, McCracken was Senior Vice President and Chief Commercial Officer at Fluidigm Corp, where he was responsible for leading all commercial activities, driving revenue growth, and expanding the Company’s global reach. McCracken has also held leadership roles at Thermo Fisher Scientific and Qiagen. 

As CEO of McCracken will focus on building strategic partnerships and customer relationships, ahead of the commercial introduction of the company’s first product, a benchtop DNA printer. The announcement comes as Evonetix continues to strengthen its senior leadership team, following the recent appointment of Paul Beastall as Chair, as the Company enters the next phase of its development, moving from pure research and development into product commercialisation. 

Official comments  

Colin McCracken, Chief Executive Officer at Evonetix, commented: “The team at Evonetix has achieved major milestones in building the technology to enable said based decentralised DNA synthesis. The Company’s technology has the potential to revolutionise synthetic biology, overcoming the limitations of centralised supply by making rapid synthesis of complex DNA libraries and genes routine in every lab. It is an honour to join Evonetix at this pivotal point in their development and I’m looking forward to working with the team to execute our vision and commercial strategy.” 

Dr Matthew Hayes, Chief Technology Officer and Founder at Evonetix, added: “We have engaged in an extensive and detailed search to find the right person to lead Evonetix into our next phase of development. Colin has impressed us with both his commercial knowledge and ability to relate to the leadership team and wider organisation. We are all looking forward to working with him and continuing to build Evonetix’s future.”  

 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free